Terms: = Germ cell tumor AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Treatment
74 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
3. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
4. Histopathologic Features for Overall Survival in Merkel cell Carcinoma: A Case Series with Intact Mismatch Repair Protein Expression.
Kestel S; Ogut B; Inan MA; Erdem O
Turk Patoloji Derg; 2023; 39(3):169-178. PubMed ID: 37350641
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
6. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
7. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
8. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract] [Full Text] [Related]
9. Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.
Rigter LS; Snaebjornsson P; Rosenberg EH; Altena E; van Grieken NCT; Aleman BMP; Kerst JM; Morton L; Schaapveld M; Meijer GA; van Leeuwen FE; van Leerdam ME;
PLoS One; 2022; 17(7):e0270591. PubMed ID: 35877698
[TBL] [Abstract] [Full Text] [Related]
10. Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance.
Hamblin R; Vardon A; Akpalu J; Tampourlou M; Spiliotis I; Sbardella E; Lynch J; Shankaran V; Mavilakandy A; Gagliardi I; Meade S; Hobbs C; Cameron A; Levy MJ; Ayuk J; Grossman A; Ambrosio MR; Zatelli MC; Reddy N; Bradley K; Murray RD; Pal A; Karavitaki N
Lancet Diabetes Endocrinol; 2022 Aug; 10(8):581-588. PubMed ID: 35780804
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract] [Full Text] [Related]
12. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions.
Hu N; Hu WH; Zhou SL; Yang Z; Liang WL; Yang RY; Li MH; Jing Z; Li ZA; Fu XD; Wang XJ
Neoplasma; 2021 Nov; 68(6):1147-1156. PubMed ID: 34427100
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
Alphones S; Chatterjee U; Singh A; Das A; Zameer L; Achari R; Bhattacharya A; Roy P
Childs Nerv Syst; 2021 Aug; 37(8):2521-2530. PubMed ID: 34097097
[TBL] [Abstract] [Full Text] [Related]
14. Pathological Findings of the Host Immune Reaction in the tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
Hasegawa S; Kobayashi N; Okubo N; Tokuhisa M; Goto A; Kurita Y; Sato T; Hosono K; Endo I; Nakajima A; Ichikawa Y
Intern Med; 2021 Apr; 60(7):977-983. PubMed ID: 33162477
[TBL] [Abstract] [Full Text] [Related]
15. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
Riccò B; Salati M; Reggiani Bonetti L; Dominici M; Luppi G
Tumori; 2020 Dec; 106(6):NP57-NP62. PubMed ID: 32878569
[TBL] [Abstract] [Full Text] [Related]
16. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carroll MR; Ramalingam P; Salvo G; Fujimoto J; Solis Soto LM; Phoolcharoen N; Hillman RT; Cardnell R; Byers L; Frumovitz M
Int J Gynecol Cancer; 2020 Sep; 30(9):1303-1307. PubMed ID: 32727929
[TBL] [Abstract] [Full Text] [Related]
18. Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of mlh1.
Gallitto M; Cheng He R; Inocencio JF; Wang H; Zhang Y; Deikus G; Wasserman I; Strahl M; Smith M; Sebra R; Yong RL
J Neurooncol; 2020 May; 147(3):557-566. PubMed ID: 32193690
[TBL] [Abstract] [Full Text] [Related]
19. Homogeneous MMR Deficiency Throughout the Entire tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract] [Full Text] [Related]
20. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract] [Full Text] [Related]
[Next]
